- Abstract:
-
UNLABELLED: Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of (111)In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. METHODS: Human EGF (hEGF) was derivatized with diethylenetriaminepentaacetic acid (DTPA) and then purified by size-exclusion chromatography and ultrafiltration. Kits were prepared by dispensing 0.25 mg (1 mL) of DTPA-hEGF in 1 mo...
Expand abstract - Publication status:
- Published
- Journal:
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Volume:
- 45
- Issue:
- 4
- Pages:
- 701-708
- Publication date:
- 2004-04-05
- EISSN:
-
1535-5667
- ISSN:
-
0161-5505
- URN:
-
uuid:6b080890-04a5-49b0-bd6d-750e528c0f35
- Source identifiers:
-
131319
- Local pid:
- pubs:131319
- Copyright date:
- 2004
Journal article
A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record